aci-7104.056 at dose c
aci-7104.056 at dose c: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: AC Immune SA (ACIU)
Development Pipeline (1)
| Company | Phase |
|---|---|
| AC Immune SA (ACIU) | Phase 2 |
Clinical Trials (1)
An Adaptive, Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
Frequently asked questions
Who is developing aci-7104.056 at dose c?
aci-7104.056 at dose c is being developed by AC Immune SA.
How many clinical trials involve aci-7104.056 at dose c?
BioSniper tracks 1 clinical trial involving aci-7104.056 at dose c.
Analyze AC Immune SA & aci-7104.056 at dose c with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company